Last updated: March 2026
Coluracetam (BCI-540) is a potent HACU enhancer that entered Phase 2a clinical trials for major depressive disorder comorbid with generalized anxiety disorder. It is uniquely known for enhancing color saturation and visual clarity — a distinct qualitative effect rarely reported with other racetams. Best administered sublingually at 20-80mg.
Coluracetam's primary mechanism is high-affinity choline uptake (HACU) enhancement — similar to pramiracetam, but at much lower doses. This increases acetylcholine synthesis in both cholinergic synapses and potentially in visual processing pathways. Its antidepressant potential may relate to cholinergic modulation of monoaminergic tone and hippocampal neuroplasticity.
Coluracetam strongly enhances the high-affinity choline transporter (CHT1) activity in hippocampal and cortical neurons. This rate-limiting step in acetylcholine biosynthesis is upregulated, increasing the amount of choline available for conversion to acetylcholine. Preclinical studies show HACU enhancement even after neuronal damage (e.g., AF64A-induced cholinotoxicity), suggesting neuroprotective properties.
The distinctive visual clarity and color saturation enhancement reported with coluracetam is thought to arise from increased acetylcholine availability in the visual cortex. The cholinergic system modulates contrast sensitivity, color discrimination, and visual attention. Enhanced ACh in visual processing circuits sharpens edge detection and may increase the perceived vividness and saturation of colors.
The cholinergic system interacts bidirectionally with serotonergic and noradrenergic circuits. Coluracetam's HACU enhancement may modulate monoamine release through cholinergic interneurons. In the BCI-540 Phase 2a trials, patients who had failed SSRI therapy showed significant response — suggesting a mechanism complementary to serotonin reuptake inhibition, potentially involving hippocampal cholinergic-dependent neuroplasticity.
Coluracetam is most effective when administered sublingually at 20-80mg. This route bypasses hepatic first-pass metabolism, increasing bioavailability and producing faster onset (~15-30 minutes) vs oral dosing. The compound dissolves readily under the tongue. Some protocols use fat co-ingestion even with sublingual dosing, though evidence for this approach is limited. Duration is approximately 3-5 hours.
Coluracetam has more clinical development history than most racetams. Originally developed by Mitsubishi Tanabe Pharma for Alzheimer's disease, it was licensed to BrainCells Inc. for mood disorder applications. Phase 2a data for MDD/GAD is the most significant clinical dataset available.
Coluracetam is active at low doses — a precision scale is essential. Always pair with a choline source.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational purposes only. It is not medical advice. Coluracetam is not FDA-approved for any indication and is sold as a research compound. Do not use as a substitute for prescribed antidepressant therapy. Always consult a qualified psychiatrist or healthcare provider before making any changes to mood disorder treatment.